Transarterial radioembolization (TARE) with yttrium-90 glass microspheres is widely
used to treat primary and secondary malignancies in the liver. However, the safety
and efficacy of TARE in patients with liver-dominant metastatic castration-resistant
prostate cancer (mCRPC) is unknown. A proof-of-concept, retrospective analysis of
7 consecutive patients with liver-dominant mCRPC who were treated with TARE was performed.
The median overall survival was 27.2, 32.1, and 108.1 months from the time of TARE,
the diagnosis of liver metastases, and initial cancer diagnosis, respectively. The
median liver progression-free survival was 7.3 months. No grade 3 or higher adverse
effects were noted. TARE was found to be a safe and effective tool for treating patients
with liver-dominant mCRPC in this limited cohort.
